TrialFrontiers in immunology2022

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.

Rafaella F Q Grenfell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.